Anthony Liftgates created the MRT-XL liftgate to help a long-time customer whose drivers were struggling to safely offload extra-large items such as hot tubs. ...
When it comes to a selloff due to the coronavirus from China, one area that's prime for bears has been the restaurant industry. But amid the historic fallout, it's now a better time to look at restaurant stocks to buy and ready 'to-go' in your portfolio.Thursday may not have elicited a full sigh of relief among investors. But a mild rise of just 0.47% in the S&P 500 and slightly spicy gain of 2.3% for the NASDAQ Composite was much better than the standard, stomach-churning fare of late. The price action also marked day one of a critical follow-through count for the broader averages, which have seen corrections of up to 32% over the last four weeks.To say the least, the overall price action within the recently crowned bear market has been painful. Supply chain disruptions, forced closures, "shelter in" mandates and sensible "safe distancing" practices have been hard on most...
JMP Securities lowered its price target on Uber from $56 to $37, but noted the ride hailing company is "well positioned to weather the COVID-19 storm." Citi also lowered its price target on the ride-hailing company from $46 to $34. Yahoo FInance’s Dan Howley joins Seana Smith to discuss....
Gilead Sciences, Inc. (NASDAQ: GILD) shares spiked about 6.6% Wednesday in reaction to a Piper Sandler note that suggested the biopharma's remdesivir could be approved for COVID-19. An analyst at BofA Securities isn't convinced of remdesivir's potential.The Gilead Analyst Analyst Geoff Meacham maintained a Neutral rating on Gilead with a $70 price target.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.The Gilead Thesis Gilead's remdesivir is the only COVID-19 treatment that is in late-stage development, with a potential readout in April, Meacham said in a Friday note. (See his track record here.)While the drug is likely to have some activity, the overall clinical benefit in COVID-19 patients could be modest, the analyst said, citing infectious disease specialists with experience in viral respiratory disease.The key opinion leaders BofA interviewed highlighted difficulties such as a high placebo effect, a high...